Business
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Webcast to be held Wednesday, May 27th at 8:00 a.m. ETSAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will h
About this update from Apogee Therapeutics, Inc.
[{"type":"image","alt":"Apogee Therapeutics","displaySize":"","headline":null,"caption":"Apogee Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84}},"lazy":false},{"type":"text","content":"Webcast to be held Wednesday, May 27th at 8:00 a.m. ET","length":54,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.","length":523,"tagName":"p"},{"type":"text","content":"Webcast Details","length":15,"tagName":"p"},{"type":"text","content":"Apogee Therapeutics’ live webcast of the Phase 2 APEX Part B results will begin on Wednesday, May 27 at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.","length":340,"tagName":"p"},{"type":"text","content":"About Apogee","length":12,"tagName":"p"},{"type":"text","content":"Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-est...